



Pericarditis (AESI) & COVID-19 Vaccine Decision Guide

Pericarditis Report to SAEFVIC

Specialist Immunisation Service (+- Cardiology) referral:
 - **Recommended** for Brighton 1-3
 - **Optional** for Brighton 4
 - **Not required** for Brighton 5 unless significant concerns

Abnormal troponin = myocarditis pathway

Abnormal ECG / Echo / CXR with normal troponin

Gather investigations / information

Investigations not available or not done

Normal investigations (ECG / Echo / CXR / Troponin)

Brighton Level 1-3

Brighton Level 4

Brighton Level 5

> 60 yo (any sex)

Female 6 mo-59 yo

Male 25-59 yo

Male 6 mo-24 yo

Female 6 mo-59 yo

Male 25-59 yo

Male 6 mo-24 yo

All age groups

Proceed with non-mRNA vaccine (AZ / NX)

Consider non-mRNA vaccine (NX) if >12yo, or can consider mRNA vaccine after discussion with patient

Caution required. Only consider further vaccine after individual risk versus benefit discussion. May consider non-mRNA vaccine (NX) if >12yo.

Proceed with next dose of same COVID-19 vaccine

Consider non-mRNA vaccine (NX) if >12yo, or can consider mRNA vaccine after discussion with patient

Proceed with next dose of same COVID-19 vaccine

Only proceed with further vaccination at a minimum of 8 weeks from initial symptom onset, AND after symptoms have completely resolved

Brighton Collaboration Criteria:
 Sexson Tejtel SK, Munoz FM, Al-Ammouri I, Savorgnan F, Guggilla RK, Khuri-Bulos N, et al. Myocarditis and pericarditis: Case definition and guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine. 2022;40(10):1499-511.

AZ = AstraZeneca* mRNA = Spikevax (Moderna), Comirnaty (Pfizer) NX = Nuvaxovid (Novavax)*
 *not currently licensed for <18yo

Updated 5/6/22